Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fat Emulsions, Intravenous | 11 | 2025 | 79 | 2.820 |
Why?
|
| Short Bowel Syndrome | 4 | 2022 | 66 | 2.740 |
Why?
|
| Enterocolitis, Necrotizing | 11 | 2023 | 248 | 2.550 |
Why?
|
| Parenteral Nutrition | 13 | 2025 | 199 | 2.310 |
Why?
|
| Cholestasis | 7 | 2025 | 157 | 1.850 |
Why?
|
| Fish Oils | 9 | 2025 | 80 | 1.660 |
Why?
|
| Intestinal Diseases | 4 | 2022 | 76 | 1.610 |
Why?
|
| Infant, Premature | 9 | 2024 | 843 | 1.520 |
Why?
|
| Ostomy | 2 | 2023 | 11 | 1.500 |
Why?
|
| Infant, Newborn, Diseases | 4 | 2023 | 180 | 1.200 |
Why?
|
| Liver Diseases | 4 | 2022 | 385 | 1.100 |
Why?
|
| Infant, Newborn | 27 | 2024 | 8548 | 1.070 |
Why?
|
| Soybean Oil | 8 | 2024 | 70 | 0.940 |
Why?
|
| Intensive Care Units, Neonatal | 4 | 2023 | 337 | 0.910 |
Why?
|
| Infant Formula | 3 | 2020 | 98 | 0.850 |
Why?
|
| Infant | 20 | 2025 | 13049 | 0.770 |
Why?
|
| Infant, Premature, Diseases | 4 | 2024 | 252 | 0.690 |
Why?
|
| Milk, Human | 3 | 2020 | 308 | 0.680 |
Why?
|
| Probiotics | 1 | 2023 | 226 | 0.670 |
Why?
|
| Central Venous Catheters | 1 | 2021 | 48 | 0.660 |
Why?
|
| Catheterization, Central Venous | 1 | 2021 | 140 | 0.620 |
Why?
|
| Intestines | 5 | 2024 | 606 | 0.610 |
Why?
|
| Fetal Diseases | 1 | 2023 | 461 | 0.600 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2019 | 168 | 0.580 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2020 | 111 | 0.580 |
Why?
|
| Argininosuccinate Lyase | 4 | 2018 | 65 | 0.560 |
Why?
|
| Enterocytes | 2 | 2018 | 75 | 0.560 |
Why?
|
| Neonatologists | 1 | 2017 | 20 | 0.550 |
Why?
|
| Thrombosis | 1 | 2021 | 528 | 0.490 |
Why?
|
| Lower Extremity Deformities, Congenital | 1 | 2014 | 7 | 0.450 |
Why?
|
| Mouth Abnormalities | 1 | 2014 | 15 | 0.450 |
Why?
|
| Syndactyly | 1 | 2014 | 24 | 0.450 |
Why?
|
| Apnea | 1 | 2014 | 31 | 0.440 |
Why?
|
| Maxilla | 1 | 2014 | 39 | 0.440 |
Why?
|
| Fingers | 1 | 2014 | 67 | 0.440 |
Why?
|
| Mandible | 1 | 2014 | 80 | 0.430 |
Why?
|
| Eye Abnormalities | 1 | 2014 | 104 | 0.420 |
Why?
|
| Knee Joint | 1 | 2014 | 172 | 0.410 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2014 | 58 | 0.400 |
Why?
|
| Cleft Lip | 1 | 2014 | 135 | 0.390 |
Why?
|
| Cleft Palate | 1 | 2014 | 154 | 0.390 |
Why?
|
| Humans | 40 | 2025 | 132257 | 0.380 |
Why?
|
| Urogenital Abnormalities | 1 | 2014 | 167 | 0.380 |
Why?
|
| Nitric Oxide | 4 | 2018 | 470 | 0.380 |
Why?
|
| Intestinal Perforation | 2 | 2024 | 56 | 0.380 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2024 | 41 | 0.360 |
Why?
|
| Enteral Nutrition | 2 | 2023 | 267 | 0.330 |
Why?
|
| Food, Fortified | 2 | 2020 | 62 | 0.310 |
Why?
|
| Scrotum | 1 | 2009 | 28 | 0.300 |
Why?
|
| Triglycerides | 4 | 2022 | 617 | 0.300 |
Why?
|
| Abnormalities, Multiple | 1 | 2014 | 982 | 0.290 |
Why?
|
| Argininosuccinic Aciduria | 3 | 2014 | 56 | 0.290 |
Why?
|
| Dietary Supplements | 2 | 2023 | 439 | 0.290 |
Why?
|
| Tuberculosis, Miliary | 1 | 2007 | 10 | 0.270 |
Why?
|
| Testis | 1 | 2009 | 423 | 0.250 |
Why?
|
| Cohort Studies | 4 | 2025 | 5176 | 0.250 |
Why?
|
| Fatty Acids, Essential | 1 | 2025 | 6 | 0.240 |
Why?
|
| Docosahexaenoic Acids | 3 | 2025 | 66 | 0.230 |
Why?
|
| Olive Oil | 2 | 2022 | 24 | 0.230 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2007 | 253 | 0.230 |
Why?
|
| Gestational Age | 3 | 2024 | 1227 | 0.230 |
Why?
|
| Birth Weight | 2 | 2023 | 351 | 0.230 |
Why?
|
| Laparotomy | 1 | 2024 | 144 | 0.200 |
Why?
|
| Ileus | 1 | 2023 | 10 | 0.200 |
Why?
|
| Drainage | 1 | 2024 | 262 | 0.190 |
Why?
|
| Arginine | 4 | 2018 | 343 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 496 | 0.190 |
Why?
|
| Intestinal Mucosa | 2 | 2018 | 797 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 576 | 0.180 |
Why?
|
| Bilirubin | 1 | 2022 | 128 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2007 | 721 | 0.180 |
Why?
|
| Retrospective Studies | 9 | 2024 | 17396 | 0.180 |
Why?
|
| Fatty Acids | 2 | 2020 | 356 | 0.180 |
Why?
|
| Male | 17 | 2025 | 65019 | 0.170 |
Why?
|
| Energy Intake | 2 | 2020 | 493 | 0.160 |
Why?
|
| Ileum | 1 | 2020 | 130 | 0.160 |
Why?
|
| Swine | 6 | 2020 | 1179 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 297 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2021 | 157 | 0.160 |
Why?
|
| Micronutrients | 1 | 2020 | 63 | 0.160 |
Why?
|
| Growth | 1 | 2020 | 95 | 0.160 |
Why?
|
| Female | 15 | 2025 | 70792 | 0.150 |
Why?
|
| Infant, Low Birth Weight | 1 | 2020 | 174 | 0.150 |
Why?
|
| Milk | 1 | 2019 | 108 | 0.150 |
Why?
|
| Premature Birth | 2 | 2020 | 418 | 0.150 |
Why?
|
| Swine Diseases | 2 | 2020 | 42 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1250 | 0.140 |
Why?
|
| Length of Stay | 1 | 2024 | 1382 | 0.140 |
Why?
|
| Cattle | 1 | 2019 | 569 | 0.140 |
Why?
|
| Emulsions | 2 | 2019 | 70 | 0.140 |
Why?
|
| Metabolome | 1 | 2020 | 324 | 0.140 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 255 | 0.140 |
Why?
|
| Sepsis | 2 | 2019 | 516 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2024 | 13031 | 0.130 |
Why?
|
| United States | 2 | 2023 | 11675 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 767 | 0.130 |
Why?
|
| Citrulline | 1 | 2018 | 115 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 382 | 0.130 |
Why?
|
| Fetal Development | 1 | 2018 | 131 | 0.130 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2008 | 63 | 0.130 |
Why?
|
| Animals | 11 | 2020 | 34850 | 0.130 |
Why?
|
| Critical Illness | 1 | 2021 | 618 | 0.130 |
Why?
|
| Colitis | 1 | 2018 | 165 | 0.120 |
Why?
|
| Smad7 Protein | 1 | 2016 | 5 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 4690 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 263 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 434 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3761 | 0.110 |
Why?
|
| Pregnancy | 4 | 2023 | 7557 | 0.110 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 65 | 0.110 |
Why?
|
| Compassionate Use Trials | 1 | 2014 | 16 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 106 | 0.100 |
Why?
|
| Child | 7 | 2024 | 25784 | 0.100 |
Why?
|
| Phospholipids | 1 | 2014 | 104 | 0.100 |
Why?
|
| Inflammation | 2 | 2018 | 1522 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3995 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 473 | 0.100 |
Why?
|
| Infant, Extremely Premature | 1 | 2014 | 108 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 241 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2012 | 42 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2014 | 186 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 515 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2018 | 3868 | 0.090 |
Why?
|
| Transfection | 1 | 2014 | 996 | 0.090 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2002 | 2 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2014 | 435 | 0.090 |
Why?
|
| Cell Line | 2 | 2014 | 2724 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 692 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2002 | 126 | 0.090 |
Why?
|
| Animals, Newborn | 1 | 2014 | 1033 | 0.080 |
Why?
|
| Risk | 1 | 2012 | 761 | 0.080 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 2017 | 211 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 890 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2014 | 631 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2002 | 327 | 0.080 |
Why?
|
| Texas | 2 | 2020 | 3632 | 0.080 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1999 | 7 | 0.080 |
Why?
|
| Fanconi Anemia | 1 | 1999 | 39 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 561 | 0.080 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 780 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 131 | 0.070 |
Why?
|
| High-Frequency Ventilation | 1 | 2008 | 20 | 0.070 |
Why?
|
| Rats | 1 | 2014 | 3607 | 0.070 |
Why?
|
| Minisatellite Repeats | 1 | 2007 | 45 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 673 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2012 | 720 | 0.070 |
Why?
|
| Apoptosis | 1 | 2014 | 1901 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 6569 | 0.060 |
Why?
|
| alpha-Linolenic Acid | 1 | 2025 | 15 | 0.060 |
Why?
|
| Linoleic Acid | 1 | 2025 | 17 | 0.060 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 299 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3093 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2025 | 67 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 394 | 0.060 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2006 | 176 | 0.060 |
Why?
|
| Spontaneous Perforation | 1 | 2024 | 4 | 0.060 |
Why?
|
| Mice | 4 | 2016 | 18507 | 0.060 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2025 | 81 | 0.060 |
Why?
|
| Liver Transplantation | 2 | 2024 | 1103 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6452 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1966 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3414 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3853 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2006 | 408 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 4758 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1128 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 415 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1500 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2024 | 1444 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 84 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2024 | 14736 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1081 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 3358 | 0.040 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 18 | 0.030 |
Why?
|
| Phytosterols | 1 | 2017 | 28 | 0.030 |
Why?
|
| Body Composition | 1 | 2019 | 550 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 172 | 0.030 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 46 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2016 | 58 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 123 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 10946 | 0.030 |
Why?
|
| Child Development | 1 | 2017 | 271 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 306 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2018 | 906 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 1125 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 454 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 3377 | 0.020 |
Why?
|
| Argininosuccinate Synthase | 1 | 2011 | 25 | 0.020 |
Why?
|
| Nitrites | 1 | 2011 | 49 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2011 | 173 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 351 | 0.020 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 554 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 2553 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 398 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2002 | 322 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2002 | 292 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 689 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1999 | 376 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 526 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 862 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 1233 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3194 | 0.020 |
Why?
|
| Adult | 1 | 2007 | 31620 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1803 | 0.010 |
Why?
|
| Liver | 1 | 2012 | 1797 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 4720 | 0.010 |
Why?
|
| Hypertension | 1 | 2012 | 1398 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 20561 | 0.010 |
Why?
|